Previous 10 | Next 10 |
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, announced today that it has promoted Andrea Matthews to Chief...
2023-03-22 12:59:03 ET Astria Therapeutics, Inc. (ATXS) Q4 2022 Earnings Conference Call March 22, 2023 08:30 AM ET Company Participants Andrea Matthews - Senior Vice President, Corporate Affairs Jill Milne - Chief Executive Officer Andy Nichols - Chief Scientifi...
2023-03-22 10:48:10 ET The following slide deck was published by Astria Therapeutics, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Astria Therapeutics, Inc. 2022 Q4 - Results - Earnings Call Presentation
2023-03-22 08:03:51 ET Astria TherapeuticS press release ( NASDAQ: ATXS ): Q4 GAAP EPS of -$0.72 misses by $0.01 . As of December 31, 2022, Astria had cash, cash equivalents, and short-term investments of $226.4 million, compared to $116.6 million as of September 30, 2...
-- ALPHA-STAR Phase 1b/2 Trial in People with HAE Underway with Initial Proof-of-Concept Results Anticipated Mid-2024 -- -- Phase 1a Results Support STAR-0215’s Target Profile as a Long-Acting Plasma Kallikrein Inhibitor with Estimated Half-Life of up to 117 Days -- -- Ende...
Astria Therapeutics, Inc. (NASDAQ:ATXS) a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, will report fourth quarter/full year 2022 financial results be...
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a c...
Gainers: OncoSec Medical ( ONCS ) +44% . BioRestorative Therapies BRTX +32% . Astria Therapeutics ( ATXS ) +13% . Certara ( CERT ) +12% . Kazia Therapeutics ( KZIA ) +11% . Losers: ZimVie ( ZIMV ) -45% . Cano Health ( CAN...
-- Additional Phase 1a Clinical Data Shows STAR-0215 Has Estimated Half-Life of up to 117 Days, Supporting Potential for Dosing Once Every Three Months or Less Frequently -- -- STAR-0215 Differentiated Plasma Kallikrein Binding is Consistent with High Specificity -- Astria The...
Summary BioCryst's main value driver, ORLADEYO, is already profitable in its second year on the market and generated over $250 million in revenue in 2022. ORLADEYO is successfully differentiating itself in a multi-billion dollar market and is on track to achieve blockbuster status in a ...
News, Short Squeeze, Breakout and More Instantly...
Astria Therapeutics Inc. Company Name:
ATXS Stock Symbol:
NASDAQ Market:
Astria Therapeutics Inc. Website:
2024-06-16 18:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data in an encore presentation at the upcoming Eastern Allerg...
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two posters at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Congress in Va...